Ignite Creation Date:
2025-12-24 @ 6:44 PM
Ignite Modification Date:
2025-12-28 @ 9:30 AM
Study NCT ID:
NCT05119257
Status:
AVAILABLE
Last Update Posted:
2024-05-08
First Post:
2021-10-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
(Bispecific) Antibodies in Cancer Patients
Sponsor:
University Hospital Tuebingen
Organization:
Study Overview
Official Title:
(Bispecific) Antibodies in Cancer Patients (InHeAb01)
Status:
AVAILABLE
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
InHeAb01
Brief Summary:
The aim of this project is to provide (bispecific) antibodies to individual patients with advanced solid and hematological malignancies without any available approved treatment options.
Detailed Description:
Ethics: Patient treatment will be conducted according to ยง13 Absatz 2b, AMG (German law).
All (bispecific antibodies) applied are developed and manufactured by the principle investigator Prof. Helmut Salih.
All (bispecific antibodies) applied are developed and manufactured by the principle investigator Prof. Helmut Salih.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: